169 related articles for article (PubMed ID: 20135728)
21. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
22. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
[TBL] [Abstract][Full Text] [Related]
23. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis.
Li H; Yuan X; Qiu L; Zhou Q; Xiao P
Ren Fail; 2014 Oct; 36(9):1404-6. PubMed ID: 25246340
[TBL] [Abstract][Full Text] [Related]
25. Viral-Associated GN: Hepatitis B and Other Viral Infections.
Kupin WL
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1529-1533. PubMed ID: 27797900
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pathological characteristics of 5 children with HBV surface antigen (HBsAg)-negative hepatitis B virus-associated glomerulonephritis.
Liu T; Yang S; Yue Z; Kuang Y; Guan W; Sun L
J Clin Virol; 2015 May; 66():1-5. PubMed ID: 25866326
[TBL] [Abstract][Full Text] [Related]
27. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Li J
Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children.
Ozdamar SO; Gucer S; Tinaztepe K
Pediatr Nephrol; 2003 Jan; 18(1):23-8. PubMed ID: 12488986
[TBL] [Abstract][Full Text] [Related]
29. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
Rizzetto M
J Med Virol; 2002 Apr; 66(4):435-51. PubMed ID: 11857520
[TBL] [Abstract][Full Text] [Related]
31. [A cohort study on the epidemiological characteristics of HBeAg sero-clearance in HBeAg positive chronic hepatitis B patients in Jiangsu province from 2012 to 2014].
Zhu LG; Jiang J; Song C; Zou Y; Xu JF; Liu HJ; Peng H; Hu ZB; Zhu FC; Shen HB; Zhai XJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):179-184. PubMed ID: 28231662
[No Abstract] [Full Text] [Related]
32. [HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy].
Lee CK; Han KH; Suh JH; Cho YS; Won SY; Chon CY; Moon YM; Park IS
Korean J Hepatol; 2005 Mar; 11(1):34-42. PubMed ID: 15788883
[TBL] [Abstract][Full Text] [Related]
33. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection.
Marrone A; Zampino R; D'Onofrio M; Ricciotti R; Ruggiero G; Utili R
J Hepatol; 2004 Dec; 41(6):1064-5. PubMed ID: 15582146
[No Abstract] [Full Text] [Related]
34. [A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years].
Zhu SS; Dong Y; Xu ZQ; Wang LM; Chen DW; Gan Y; Wang FC; Yan JG; Cao LL; Wang P; Zhang HF
Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):738-743. PubMed ID: 27938558
[No Abstract] [Full Text] [Related]
35. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
36. Current pharmacotherapy for the treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Expert Opin Pharmacother; 2003 Oct; 4(10):1821-7. PubMed ID: 14521491
[TBL] [Abstract][Full Text] [Related]
37. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials.
Rudin D; Shah SM; Kiss A; Wetz RV; Sottile VM
Liver Int; 2007 Nov; 27(9):1185-93. PubMed ID: 17919229
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
[TBL] [Abstract][Full Text] [Related]
40. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
